Allurion reports initial results on Allurion Program, tirzepatide combination

Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. In total, 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and increased to no greater than 5mg over the subsequent 2 months, considerably lower than standard dosing which can increase to 15mg. Tirzepatide therapy was continued for 8 months and final results were measured 2 months after discontinuation, for a total follow-up period of 12 months. Patients were followed using the AI-powered Virtual Care Suite as part of the Allurion Program. After 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. No patients discontinued early, and all patients remained adherent to tirzepatide for the duration of the study. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit, due in part to side effects, dose escalation required for continued weight loss, and cost. In addition, a recent study published in JAMA Internal Medicine shows that following withdrawal of tirzepatide, a higher degree of weight regain was associated with a greater reversal of initial improvements in waist circumference, blood pressure, non-high-density lipoprotein cholesterol, glycemic parameters, and insulin resistance. Additional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.